NCT06233292View on ClinicalTrials.gov

A Study of ZG005 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

484

Participants

Timeline

Start Date

June 17, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Solid Tumors
Interventions
BIOLOGICAL

ZG005 Powder for Injection

The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.

BIOLOGICAL

ZG005 Powder for Injection

Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY